标题：Research Grade Trastuzumab曲妥珠单抗,AntibodySystem Laboratories
链接：https://www.antibodysystem.com/product/10037.html
名称：Research Grade Trastuzumab曲妥珠单抗
别名：Trastuzumab曲妥珠单抗，timigutuzumab, 4D5-8, 4D5V8, Herceptin, rhuMab HER2,
CAS: 180288-69-1
货号：DHC09601
适用物种：Human
寄主物种：Humanized
形式：Liquid
纯度：>95%
克隆性：Monoclonal
同种型：IgG1, kappa
应用：Research Grade Biosimilar
UniProt：P04626
靶点：p185erbB2, HER2, NGL, Tyrosine kinase-type cell surface receptor HER2, NEU, MLN 19, Proto-oncogene Neu, MLN19, ERBB2, Proto-oncogene c-ErbB-2, CD340, Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein
用途范围：仅用于科研
储存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
免费热线：027-65279366 /18108604356
QQ：2663991332
咨询邮箱：products@biolabreagent.com
选购商城：https://www.antibodysystem.com
微信公众平台：佰乐博生物Biolab Reagents
参考文献：
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. PMID: 36495879
Trastuzumab Deruxtecan: First Approval. PMID: 32144719
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer. PMID: 36587473
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. PMID: 28215665
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. PMID: 32213540
[Trastuzumab and its biosimilars]. PMID: 29813044
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. PMID: 33480963
Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors. PMID: 33946310
Disrupting Circadian Rhythm via the PER1-HK2 Axis Reverses Trastuzumab Resistance in Gastric Cancer. PMID: 35255118
Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric cancer. PMID: 37434399
Targeting HER2-positive breast cancer: advances and future directions. PMID: 36344672
Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. PMID: 37279095
Trastuzumab Deruxtecan in HER2-Low Breast Cancer. Reply. PMID: 36130006
Adjuvant trastuzumab: a 10-year overview of its benefit. PMID: 27883296
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure. PMID: 37467660
Trastuzumab Deruxtecan for Breast Cancer. PMID: 35704495
Flashback Foreword: Activity of First-Line Trastuzumab. PMID: 36921334
Monitoring Trastuzumab Resistance and Cardiotoxicity: A Tale of Personalized Medicine. PMID: 26231486
Trastuzumab deruxtecan for breast cancer: do patients experience a comprehensive benefit? PMID: 37349024
Trastuzumab Deruxtecan in HER2-Low Breast Cancer. PMID: 36130005
Trastuzumab Deruxtecan for Breast Cancer. Reply. PMID: 35704496
Efficacy and safety of the trastuzumab biosimilar candidate CT-P6. PMID: 29482364
Trastuzumab administration during pregnancy: an update. PMID: 33902516
Trastuzumab-induced human cardiomyocyte damage through the Notch2/JAK2/STAT3 pathway. PMID: 37567042
Safety of trastuzumab deruxtecan: A meta-analysis and pharmacovigilance study. PMID: 36200429
Association between trastuzumab and papilledema. PMID: 33419593
How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed? PMID: 35272131
Trastuzumab-based therapy is effective for salivary duct carcinoma: Case report and review of the literature. PMID: 30827840
The novel beta-TrCP protein isoform hidden in circular RNA confers trastuzumab resistance in HER2-positive breast cancer. PMID: 37783059
Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab. PMID: 31620980
Trastuzumab Deruxtecan DESTINY for Some Cancers. PMID: 32487568
Trastuzumab-Induced Thrombocytopenia Correlated by Drug-Dependent Platelet Antibodies. PMID: 33270522
Blocking soluble TNFalpha sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression. PMID: 36889811
Trastuzumab immunogenicity development in patients' sera and in laboratory animals. PMID: 33607941
Could Some Reports of Trastuzumab Cardiotoxicity Be a Surveillance Artifact? PMID: 35878103
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer. PMID: 36773612
Trastuzumab and pertuzumab in hemodialysis: A case report. PMID: 33779370
Trastuzumab-based near-infrared photoimmunotherapy in xenograft mouse of breast cancer. PMID: 36259134
Trastuzumab emtansine and cost-based decision making. PMID: 28091366
Is weight-based IV dosing of trastuzumab preferable to SC fixed-dose in some patients? A systematic scoping review. PMID: 33799233
Structure-Activity Relationships of Antibody-Drug Conjugates: A Systematic Review of Chemistry on the Trastuzumab Scaffold. PMID: 35801843
